Maravai LifeSciences (MRVI)

• Market cap: $285M
• 1 day: -4.35%
• 5 days: -4.35%
• 1 month: 2.06%
• 3 months: -53.95%
• 6 months: -65.74%
• Year to date: -63.93%
• 1 year: -79.92%
• 5 years: -93.37%
• 10 years: -93.37%
• Sector: Healthcare
• Industry: Biotechnology

About: Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Employees: 570

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

737% more call options, than puts

Call options by funds: $2.11M | Put options by funds: $252K

5% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 62

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

2.99% less ownership

Funds ownership: 101.71% [Q3] → 98.72% (-2.99%) [Q4]

17% less funds holding

Funds holding: 216 [Q3] → 180 (-36) [Q4]

36% less capital invested

Capital invested by funds: $1.2B [Q3] → $765M (-$432M) [Q4]

58% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 57

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2.50 26% upside
• Avg. target: $4.63 134% upside
• High target: $8 304% upside

4 analyst ratings

• positive: 1 25%
• neutral: 3 75%
• negative: 0 0%

Morgan Stanley Tejas Savant 30% 1-year accuracy 6 / 20 met price target	153% upside $5	Equal-Weight Maintained	25 Mar 2025
UBS Dan Brennan 32% 1-year accuracy 8 / 25 met price target	26% upside $2.50	Neutral Maintained	21 Mar 2025
B of A Securities Michael Ryskin 60% 1-year accuracy 3 / 5 met price target	304% upside $8	Buy Maintained	3 Mar 2025
Baird Catherine Schulte 6% 1-year accuracy 1 / 18 met price target	52% upside $3	Neutral Downgraded	26 Feb 2025